MY126450A - Crystalline efavirenz - Google Patents

Crystalline efavirenz

Info

Publication number
MY126450A
MY126450A MYPI99002384A MYPI19992384A MY126450A MY 126450 A MY126450 A MY 126450A MY PI99002384 A MYPI99002384 A MY PI99002384A MY PI19992384 A MYPI19992384 A MY PI19992384A MY 126450 A MY126450 A MY 126450A
Authority
MY
Malaysia
Prior art keywords
efavirenz
crystalline
crystalline efavirenz
differaction
hiv
Prior art date
Application number
MYPI99002384A
Other languages
English (en)
Inventor
B Maurin Michael
A Radesca Lilian
R Rabel Shelley
R Moore James
Original Assignee
Bristol Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22214647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY126450(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Pharma Company filed Critical Bristol Myers Squibb Pharma Company
Publication of MY126450A publication Critical patent/MY126450A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MYPI99002384A 1998-06-11 1999-06-10 Crystalline efavirenz MY126450A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8898198P 1998-06-11 1998-06-11

Publications (1)

Publication Number Publication Date
MY126450A true MY126450A (en) 2006-10-31

Family

ID=22214647

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99002384A MY126450A (en) 1998-06-11 1999-06-10 Crystalline efavirenz

Country Status (21)

Country Link
EP (1) EP1086087A1 (pl)
JP (1) JP2002517487A (pl)
CN (1) CN1307568A (pl)
AR (3) AR018670A1 (pl)
AU (1) AU758114C (pl)
BR (1) BR9911523A (pl)
CA (1) CA2333550A1 (pl)
EE (1) EE05547B1 (pl)
HR (1) HRP990182A2 (pl)
HU (1) HUP0103819A3 (pl)
IL (1) IL139793A (pl)
MY (1) MY126450A (pl)
NO (1) NO20006255L (pl)
NZ (1) NZ507713A (pl)
PL (1) PL198504B1 (pl)
SG (3) SG111980A1 (pl)
SK (1) SK18182000A3 (pl)
TW (1) TWI235152B (pl)
UA (1) UA74324C2 (pl)
WO (1) WO1999064405A1 (pl)
ZA (1) ZA200006173B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
US7205402B2 (en) * 2004-09-02 2007-04-17 Bristol-Myers Squibb Company Synthesis of a benzoxazinone
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
WO2009011567A1 (en) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Crystalline forms of efavirenz
CA2712574C (en) 2008-02-04 2014-01-07 Pfizer Limited Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases
US8383811B2 (en) 2008-12-22 2013-02-26 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
CN102924398B (zh) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 用于除去依非韦伦对应异构体的方法
US9468646B2 (en) 2013-01-23 2016-10-18 Alienor Farma Increased dosage of efavirenz for the treatment of cancer
CN105037175B (zh) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 一种用于提高依非韦伦中间体光学纯度的方法
CN105001101B (zh) * 2015-05-28 2017-11-28 乐平市瑞盛制药有限公司 一种4‑氯‑2‑三氟乙酰基苯胺水合物盐酸盐的合成方法
CN108947855B (zh) * 2018-08-10 2021-10-22 江苏沙星化工有限公司 一种依非韦伦关键中间体的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
CA2260922A1 (en) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcriptase inhibitors
ES2203790T3 (es) * 1996-10-02 2004-04-16 Bristol-Myers Squibb Pharma Company 1,4-dihidro-2h-3,1-benzoxacin-2-onas 4,4-disustituidas utiles como inhibidores de la transcriptasa reversa del hiv e intermedios y procedimientos para su preparacion.
HU229087B1 (en) * 1997-02-05 2013-07-29 Merck Sharp & Dohme Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent

Also Published As

Publication number Publication date
AU758114C (en) 2003-10-30
AR018670A1 (es) 2001-11-28
EE200000743A (et) 2002-10-15
SG111980A1 (en) 2005-06-29
PL198504B1 (pl) 2008-06-30
TWI235152B (en) 2005-07-01
CA2333550A1 (en) 1999-12-16
NO20006255D0 (no) 2000-12-08
AU4436499A (en) 1999-12-30
PL345221A1 (en) 2001-12-03
EP1086087A1 (en) 2001-03-28
HUP0103819A2 (hu) 2002-02-28
SK18182000A3 (sk) 2001-08-06
IL139793A (en) 2006-10-31
NZ507713A (en) 2003-08-29
SG111981A1 (en) 2005-06-29
ZA200006173B (en) 2001-10-31
IL139793A0 (en) 2002-02-10
HRP990182A2 (en) 2000-02-29
NO20006255L (no) 2001-02-12
BR9911523A (pt) 2001-09-18
SG134977A1 (en) 2007-09-28
UA74324C2 (uk) 2005-12-15
WO1999064405A1 (en) 1999-12-16
CN1307568A (zh) 2001-08-08
JP2002517487A (ja) 2002-06-18
HUP0103819A3 (en) 2003-05-28
AR077469A2 (es) 2011-08-31
EE05547B1 (et) 2012-06-15
AU758114B2 (en) 2003-03-13
AR077407A2 (es) 2011-08-24

Similar Documents

Publication Publication Date Title
MY126450A (en) Crystalline efavirenz
ZA9711607B (en) Novel cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
ZA9711606B (en) Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
CA2101572A1 (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
EA200001030A1 (ru) Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
LU91433I2 (fr) "Tenofovir disoproxil et les sels, en particulier le fumarate, hydrates, tautomers et solvates en combination avec l'emtricitabine et l'efavirenz (ATRIPLA)
DE69019533D1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
BR9811298A (pt) Uso de um composto de vanádio fisiologicamente aceitável
BR9509975A (pt) Formulação farmacêutica
CA2163348A1 (en) Calanolide and Related Antiviral Compounds, Compositions, and Uses Thereof
TW371662B (en) Antiviral acyclic phosphonomethoxyalkyl substituted alkenyl purine and pyrimidine derivatives
EA200100494A3 (ru) Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гипатита-b
AU6122994A (en) Hiv protease inhibitors and their preparation
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
HUP0000344A2 (hu) Lamivudint és zidovudint tartalmazó gyógyszerkészítmények
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
GR3024226T3 (en) Antiviral naphthoquinone compounds, compositions and uses thereof.
NZ294878A (en) Water soluble derivatives of epipodophyllotoxin and medicaments
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
IL93599A0 (en) Kit and/or composition for the prevention or treatment of aids
BG106151A (en) Pharmaceutical complex
SE9402241D0 (sv) Inhibitor
AU6539900A (en) Thiophene-ethyl thiourea compounds and their use in the treatment of hiv